Stanford receives funding for unique cancer and stem cell biology institute

December 10, 2002

STANFORD, Calif. -- Stanford University has received a $12 million commitment from an anonymous donor to establish a new Institute for Cancer/Stem Cell Biology and Medicine, a multi-disciplinary initiative that is believed to be the first of its kind in the country, it was announced today. The institute will bring together basic and clinical scientists in a unified effort that will harness the power of stem cell biology and cancer biology to develop novel treatments for cancer as well as other devastating diseases such as diabetes, Parkinson's disease and cardiovascular disease. The institute will be directed by renowned stem cell researcher Irving Weissman, MD, the Karel H. and Avice N. Beekhuis Professor in Cancer Biology.

"This is a major undertaking that will capitalize on Stanford's expertise in stem cell and cancer research. It exemplifies our goal of translating the fruits of laboratory research into therapies that will directly benefit patients," said Philip A. Pizzo, MD, dean of the School of Medicine and a distinguished cancer researcher.

Weissman said research in his lab and elsewhere suggests that in some cancers, such as leukemia, the cancer cells grow and proliferate in much the same way as stem cells. Scientists at the new institute will explore these similarities with the goal of developing powerful new stem cell-based therapies to treat cancer, he said.

"What we're doing is examining these two fields that we thought were separate and looking at the overlap that exists between them," Weissman said.

He said institute scientists also will work to develop a new series of embryonic stem cell lines that will serve as models for a wide range of genetically related diseases including cancer, diabetes, cardiovascular disease, autoimmune disease, allergies and neurodegenerative disorders such as Parkinson's and Lou Gehrig's disease.

"We want to translate the advances in embryonic stem cell research to create lines that represent genetically determined diseases and make these lines available to investigators who want to understand and treat these diseases," he said.

The institute will build on the long-standing history in stem cell and cancer research at Stanford University School of Medicine. Weissman was the first to isolate blood-forming stem cells in mice in 1988. In 1992, he isolated human blood-forming stem cells. He collaborated with Robert Negrin, MD, professor of medicine, and others in a clinical trial in which purified stem cells were used effectively to treat women with advanced, metastatic breast cancer. More recently, Seung Kim, PhD, assistant professor of developmental biology, and colleagues reported using embryonic stem cells to produce insulin to keep diabetic mice alive, while Judith Shizuru, MD, assistant professor of medicine, has had good results in using stem cells to treat autoimmune disease.

"The Institute for Cancer/Stem Cell Biology and Medicine will serve as a prototype for Stanford's commitment to form interdisciplinary research programs that bring together scientists and clinicians dedicated to improving the health of children and adults," said Pizzo, the Carl and Elizabeth Naumann Professor at the School of Medicine.

The institute will support existing efforts at the School of Medicine while seeking to attract additional scientists who are internationally recognized in the fields of stem cell and cancer biology, Weissman said. The institute also will spearhead efforts to have Stanford designated as a comprehensive cancer center by the National Cancer Institute, he added.

The institute's work will be integrated into the educational program of the School of Medicine, allowing students to opt for a five-year medical degree program in cancer and/or stem cell research and training. These trainees ultimately could be the seed for novel cancer and stem cell research and clinical programs around the country, Weissman said.

The institute will have two deputy directors Karl Blume, MD, professor of medicine and former director of the bone marrow transplantation program, who will serve as the clinical investigation director; and a director of scientific affairs who has yet to be named. The institute will be overseen by an executive committee of leading Stanford clinicians and scientists. Stanford also will recruit a medical director for the Clinical Cancer Center now under construction, a facility designed to promote collaboration between clinicians and researchers.

While the initial $12 million commitment will serve as seed money for the institute, Stanford will seek funds from public and private sources to sustain and enhance the endeavor.
Stanford University Medical Center integrates research, medical education and patient care at its three institutions Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at

Ruthann Richter
Director of Media Relations
Office of Communication and Public Affairs
Stanford University Medical Center
701 Welch Road, Suite 2207
Palo Alto, Ca. 94306
phone 650-725-8047
fax 650-723-6911

Stanford University Medical Center

Related Stem Cells Articles from Brightsurf:

SUTD researchers create heart cells from stem cells using 3D printing
SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Read More: Stem Cells News and Stem Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to